ArticleThe Journal of clinical investigation2008
The calm after the cytokine storm: lessons from the TGN1412 trial.
Article in The Journal of clinical investigation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 76 citations in OpenAlex.
- Dynamics of a cytokine storm.PloS one · 2012Trial
- Advancing FDA New Approach Methodologies from animal models through digital twins.NPJ digital medicine · 2026Review
- An evolutionary T119R substitution in the macaque T-cell immunoreceptor TIGIT enables proteolytic shedding and reveals clinical antibody vulnerabilities.The Journal of biological chemistry · 2026Article
- CD28 and ICOS in immune regulation: Structural insights and therapeutic targeting.Bioorganic & medicinal chemistry letters · 2025Review
- Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model.Blood advances · 2024Article
- Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors.Oncoimmunology · 2022Review
- Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases.Human vaccines & immunotherapeutics · 2021Review
- Immunopathogenesis and treatment of cytokine storm in COVID-19.Theranostics · 2021Review
- In vitro toxicity model: Upgrades to bridge the gap between preclinical and clinical research.Bosnian journal of basic medical sciences · 2020Review
- Ebola virus-mediated T-lymphocyte depletion is the result of an abortive infection.PLoS pathogens · 2019Article
- Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals.British journal of clinical pharmacology · 2019Review
- Regulatory Affairs 101: Introduction to Investigational New Drug Applications and Clinical Trial Applications.Clinical and translational science · 2019Article
- Structure and Composition Define Immunorecognition of Nucleic Acid Nanoparticles.Nano letters · 2018Article
- Avoiding Exploitation in Phase I Clinical Trials: More than (Un)Just Compensation.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2018Article
- Cancer and Aging - the Inflammatory Connection.Aging and disease · 2017Review
- Article
- Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.ALTEX · 2016Review
- Translating Treg Therapy in Humanized Mice.Frontiers in immunology · 2015Review
- Immunotherapeutic strategies in autoimmune uveitis.Autoimmunity reviews · 2014Review
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In March 2006, a phase I study of the superagonistic anti-CD28 antibody TGN1412 caused a massive cytokine storm and multiorgan failure in six healthy human volunteers. Such a profound impact on the immune system was not predicted by preclinical animal studies. In a study from this issue of the JCI, Müller et al. treated rats with the superagonistic anti-CD28 antibody JJ316 and found that it rapidly induced a marked T cell lymphopenia by trapping T cells in the spleen and lymph nodes (see the related article beginning on page 1405). This dramatic redistribution of T cells simulated the profound T cell lymphopenia observed in human recipients of TGN1412. In contrast, JJ316 treatment in the rats did not reproduce the massive cytokine storm observed following TGN1412 administration to the human volunteers. These results point to similarities as well as differences between rodents and humans in the immunological effects of superagonistic anti-CD28 antibody treatment and raise further questions about how best to design preclinical studies that can better predict the risks of novel immunotherapeutics in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.